Search
Galapagos NV
GLPGAdd to Watchlist
27.730USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
1.83BMarket Cap
4.32P/E TTM
More Details of Galapagos NV Company
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Galapagos NV Info
Ticker SymbolGLPG
Company nameGalapagos NV
IPO dateMay 06, 2005
CEOGosebruch (Henry)
Number of employees704
Security typeDepository Receipt
Fiscal year-endMay 06
AddressGeneraal De Wittelaan L11 A3
CityMALINES (MECHELEN)
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryBelgium
Postal code2800
Phone3215342900
Websitehttps://www.glpg.com/
Ticker SymbolGLPG
IPO dateMay 06, 2005
CEOGosebruch (Henry)
Company Executives of Galapagos NV
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Srikant Ramaswami
Mr. Srikant Ramaswami
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
--
--
Mr. Henry Gosebruch
Mr. Henry Gosebruch
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Aaron L. Cox
Mr. Aaron L. Cox
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Sooin Kwon
Ms. Sooin Kwon
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.08B
97.20%
Europe
31.10M
2.80%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 4
Updated: Mon, May 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences, Inc
25.35%
Tang Capital Management, LLC
5.95%
Madison Avenue Partners LP
3.36%
EcoR1 Capital, LLC
2.53%
Columbia Threadneedle Investments (US)
2.20%
Other
60.60%
Shareholders
Shareholders
Proportion
Gilead Sciences, Inc
25.35%
Tang Capital Management, LLC
5.95%
Madison Avenue Partners LP
3.36%
EcoR1 Capital, LLC
2.53%
Columbia Threadneedle Investments (US)
2.20%
Other
60.60%
Shareholder Types
Shareholders
Proportion
Corporation
25.35%
Hedge Fund
14.68%
Investment Advisor/Hedge Fund
5.86%
Investment Advisor
1.38%
Research Firm
0.19%
Sovereign Wealth Fund
0.14%
Venture Capital
0.04%
Bank and Trust
0.03%
Pension Fund
0.01%
Other
52.32%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
195
14.75M
22.38%
-7.51M
2025Q4
194
15.28M
23.19%
-6.80M
2025Q3
184
15.18M
23.04%
-2.60M
2025Q2
174
14.68M
22.27%
-2.19M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences, Inc
16.71M
25.35%
--
--
Dec 31, 2025
Tang Capital Management, LLC
3.92M
5.95%
-371.88K
-8.66%
Dec 31, 2025
Madison Avenue Partners LP
2.21M
3.36%
+17.39K
+0.79%
Dec 31, 2025
EcoR1 Capital, LLC
1.67M
2.53%
--
--
Dec 31, 2025
Columbia Threadneedle Investments (US)
1.45M
2.2%
+34.30K
+2.42%
Dec 31, 2025
Prosight Capital
1.07M
1.63%
-75.89K
-6.60%
Dec 31, 2025
Point72 Asset Management, L.P.
486.21K
0.74%
+42.34K
+9.54%
Dec 31, 2025
Greenlight Capital, Inc.
482.75K
0.73%
--
--
Dec 31, 2025
Segall Bryant & Hamill, LLC
448.10K
0.68%
-39.10K
-8.03%
Dec 31, 2025
Millennium Management LLC
339.35K
0.52%
+186.45K
+121.94%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Medical Breakthroughs ETF
0.88%
iShares Biotechnology ETF
0.1%
Avantis International Small Cap Equity ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.05%
ActivePassive International Equity ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
Avantis Responsible International Equity ETF
0%
ALPS Medical Breakthroughs ETF
Proportion0.88%
iShares Biotechnology ETF
Proportion0.1%
Avantis International Small Cap Equity ETF
Proportion0.09%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
ActivePassive International Equity ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
Avantis International Equity ETF
Proportion0.01%
iShares Health Innovation Active ETF
Proportion0%
Avantis Responsible International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
